Maturity-onset diabetes of the young (MODY) describes a set of inherited forms of diabetes caused by mutations in a single gene that alter pancreatic beta‑cell function. Unlike autoimmune type 1 diabetes or the metabolic insulin resistance often seen in type 2, MODY is usually monogenic and often follows an autosomal dominant pattern. The name MODY has been used since the mid-20th century to group clinically similar but genetically distinct disorders within the broader category of diabetes mellitus.
Genetics and mechanism
MODY results from mutations that reduce or change insulin production or secretion. Different subtypes are linked to different genes that encode glucokinase, transcription factors or other proteins important for glucose sensing and insulin release. Family history across multiple generations and targeted genetic testing can confirm a diagnosis; resources for testing and interpretation are available (genetic testing resources).
Common subtypes and clinical clues
- MODY2 (glucokinase/GCK): typically causes mild, stable fasting hyperglycaemia present from birth or childhood; many people maintain acceptable control with diet and monitoring and often do not need pharmacologic therapy (MODY subtype overview).
- MODY3 (HNF1A): often progressive with higher risk of symptomatic hyperglycaemia; this subtype frequently responds to low-dose sulfonylureas and may eventually require insulin (clinical summaries).
- MODY1 (HNF4A) and other rarer forms affect transcription factors or enzymes; each has distinguishing features that guide testing and management.
Diagnosis and differential diagnosis
Clinicians should suspect MODY when hyperglycaemia appears at a young age without typical autoimmune markers of type 1, when there is a strong multigenerational family history of non‑insulin‑dependent diabetes, or when the clinical course is atypical for type 2. Laboratory evaluation commonly includes measurement of C‑peptide and autoantibodies and, when indicated, targeted genetic sequencing. Distinguishing MODY from type 1 and type 2 is important because it changes treatment choices and informs family counselling (diabetes references).
Treatment and management
Management depends on the specific genetic subtype and degree of hyperglycaemia. Some people with GCK‑MODY (MODY2) require only lifestyle measures and monitoring. People with HNF1A‑MODY often respond to specific oral agents and may have prolonged response to sulfonylureas; insulin therapy is reserved for insufficient control or particular subtypes (treatment options) and when needed should follow principles of insulin therapy. Regular monitoring, cardiovascular risk assessment and individualized targets are part of long‑term care.
Pregnancy, family implications and prognosis
Genetic diagnosis has implications for pregnancy management, predictive testing of relatives and reproductive counselling. Some subtypes affect fetal growth or the need for perinatal glucose management. Body weight varies among people with MODY—some are lean while others may be overweight—so excess weight does not exclude the diagnosis (body weight considerations).
Practical note: MODY is often underrecognised and can be misclassified as type 1 or type 2 diabetes; identifying the correct genetic subtype allows more precise therapy, informs prognosis and enables targeted testing of relatives. For clinicians and patients seeking further detail, genetic testing resources and clinical guidance can help determine the most appropriate follow‑up (testing and interpretation, subtype information, management options).